Proteomics International (ASX:PIQ) - Managing Director, Dr Richard Lipscombe
Managing Director, Dr Richard Lipscombe
Source: Proteomics International
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Proteomics International Laboratories (PIQ) has received a $1.1 million research and development (R&D) tax incentive for the 2020 financial year
  • Throughout FY20, the company spent $2.62 million on R&D, making it eligible for a rebate of $1,138,815
  • Coupled with the recent $6 million placement, Proteomics is well-funded to continue with the commercialisation of its PromarkerD test
  • PromarkerD is a simple blood test that uses a unique protein ‘fingerprint’ to detect the onset of diabetic kidney disease up to four years before symptoms appear
  • Proteomics is steady on the market and shares are currently trading for 50.5 cents each

Proteomics International Laboratories (PIQ) has received a $1.1 million research and development (R&D) tax incentive for the 2020 financial year.

Throughout FY20, Proteomics spent $2.62 million on R&D, making it eligible for a rebate of $1,138,815.

Coupled with its recent $6 million share placement, Proteomics is well-funded to continue with the commercialisation of its PromarkerD test.

PromarkerD is a simple, low-cost blood test which uses a unique protein ‘fingerprint’ to detect the onset of diabetic kidney disease up to four years before symptoms appear.

It allows patients to apply preventative measures before kidney damage occurs, leading to better outcomes for the patient and simplified care for physicians.

Clinical studies have shown it correctly predicts 86 per cent of previously disease free patients who went on to develop chronic kidney disease.

There is currently no other test for predicting a patient’s risk of developing kidney disease, as the current processes only detect the disease once there has already been damage to the organs.

These processes include a blood or urine test which are not always reliable.

Proteomics is steady on the market and shares are trading for 50.5 cents each at 1:24 pm AEDT.

PIQ by the numbers
More From The Market Online
Image of a copper atom

Clarity scribes deal on delivery of copper 64 isotopes

Clarity Pharmaceuticals Ltd has seen its share price leap after it announced a deal with Nusano…
Closeup of an inhaler

InhaleRX sets up Phase 1 trial for panic disorder inhaler

InhaleRX Ltd has executed a Study Order with iNGENÅ« CRO Pty Ltd to oversee its Phase…
Nasal spray

‘Expansion’ the watchword in Firebrick’s sales-heavy quarter

Firebrick Pharma Ltd has recorded a busy March quarter for 2025, marked by its move into…
Kava drink and plant root

The Calmer Co’s Fiji Kava product hitting Woolworths stores

The Calmer Co International Ltd is expanding its dominance in Australia's retail sector with the entry…